A 53-year-old cancer patient developed celiac disease four months after receiving a stem cell transplant for multiple myeloma, presenting with severe diarrhea and weight loss. According to Gram Research analysis, intestinal biopsy confirmed celiac disease with markedly elevated antibodies (>123 U/mL), and a gluten-free diet completely resolved symptoms within 2 weeks. This rare case shows that immune system recovery after transplant can unmask hidden autoimmune diseases, and doctors should test for celiac disease when cancer patients have persistent digestive problems.
A 53-year-old woman being treated for blood cancer with a stem cell transplant developed unexpected digestive problems four months later. Doctors initially thought her diarrhea and weight loss were from infection or medication side effects, but testing revealed she had developed celiac disease, an autoimmune condition where the body reacts to gluten. According to Gram Research analysis, this case highlights how cancer treatments can sometimes trigger hidden autoimmune diseases during the immune system’s recovery. A gluten-free diet completely resolved her symptoms within two weeks, showing that doctors need to consider celiac disease when cancer patients have ongoing digestive issues after transplants.
Key Statistics
A case report published in 2026 documented a 53-year-old woman who developed celiac disease 4 months after autologous stem cell transplant for multiple myeloma, with intestinal biopsy confirming Marsh 3A disease and tissue transglutaminase IgA antibodies exceeding 123 U/mL.
In this case report, a gluten-free diet resulted in complete resolution of diarrhea within 2 weeks and subsequent decline in celiac serologic markers in a post-transplant patient.
The case highlights that immune reconstitution following stem cell transplantation may unmask previously subclinical autoimmune diseases such as celiac disease in cancer patients.
The Quick Take
- What they studied: Whether celiac disease (a gluten sensitivity condition) can develop in cancer patients after receiving a stem cell transplant, and how to recognize it
- Who participated: One 53-year-old woman with multiple myeloma (a type of blood cancer) who received a stem cell transplant as part of her cancer treatment
- Key finding: The patient developed celiac disease four months after her transplant, which was diagnosed through intestinal biopsy and blood tests showing high levels of celiac antibodies (>123 U/mL). A gluten-free diet completely stopped her diarrhea within 2 weeks.
- What it means for you: If you or someone you know has ongoing digestive problems after cancer treatment, doctors should test for celiac disease, not just assume it’s from medication or infection. Early diagnosis and a gluten-free diet can quickly resolve symptoms.
The Research Details
This is a case report, which means doctors documented one patient’s medical story in detail. The patient was a 53-year-old woman being treated for multiple myeloma (cancer of blood cells) with chemotherapy drugs followed by a stem cell transplant. After the transplant, she developed severe diarrhea and lost 4 kilograms (about 9 pounds) without trying. Doctors ran tests to rule out infection and cancer returning, but found neither.
To find the real cause, doctors performed an upper endoscopy, a procedure where a small camera goes down the throat to look at the intestines. They took tissue samples (biopsies) from the small intestine and found damage typical of celiac disease. Blood tests confirmed this by showing very high levels of antibodies (immune proteins) that attack gluten, a protein found in wheat, barley, and rye.
When the patient switched to a gluten-free diet, her diarrhea stopped completely within 2 weeks, and her antibody levels dropped. This case report suggests that the immune system’s recovery after stem cell transplants might activate hidden autoimmune diseases like celiac disease.
Case reports are important because they alert doctors to rare complications they might otherwise miss. When cancer patients have ongoing digestive problems after transplants, doctors typically blame infection, medication side effects, or cancer returning. This case shows that autoimmune diseases like celiac disease should also be considered, especially since the immune system is rebuilding after transplant.
This is a single case report, which is the lowest level of research evidence. However, it serves an important purpose: alerting the medical community to a rare but treatable condition. The diagnosis was confirmed with multiple tests (endoscopy, biopsy, and blood tests), and the patient’s rapid improvement on a gluten-free diet supports the diagnosis. The main limitation is that we don’t know if this is truly rare or if it’s simply underdiagnosed. The doctors couldn’t definitively rule out whether the cancer medication (lenalidomide) might have also contributed to the digestive problems.
What the Results Show
The patient presented with persistent diarrhea and unintentional weight loss (4 kg) beginning four months after her stem cell transplant for multiple myeloma. Initial investigations ruled out infection and cancer recurrence. Upper endoscopy revealed villous atrophy (flattening of the intestinal lining), and intestinal biopsy confirmed Marsh 3A celiac disease, a moderate form of the condition. Blood tests showed markedly elevated tissue transglutaminase (tTG) IgA antibodies at greater than 123 U/mL, which is diagnostic for celiac disease.
The patient was started on a strict gluten-free diet. Within 2 weeks, her diarrhea completely resolved. Over the following weeks and months, her celiac antibody levels declined, confirming that the gluten-free diet was treating the underlying condition. She maintained complete remission from her multiple myeloma throughout this period.
This case demonstrates that celiac disease can emerge during immune reconstitution after stem cell transplant. The timing (4 months post-transplant) coincides with when the immune system is actively rebuilding, which may explain why a previously subclinical autoimmune condition became clinically apparent.
The doctors considered whether the cancer medication lenalidomide might have caused the diarrhea, as this is a known side effect. However, they couldn’t definitively rule this out because they didn’t stop and restart the medication to test this theory. Additionally, the patient’s celiac serology (blood tests) and HLA typing (genetic markers associated with celiac disease) were not available from before the transplant, so doctors couldn’t confirm whether she had celiac disease before the transplant or if it truly developed afterward.
Celiac disease developing after stem cell transplant is extremely rare and not well-documented in medical literature. This case is notable because it highlights an underrecognized complication. Doctors know that stem cell transplants can trigger other autoimmune conditions during immune recovery, but celiac disease is rarely considered in the differential diagnosis of post-transplant gastrointestinal symptoms. The case report emphasizes that clinicians should broaden their thinking when cancer patients have persistent digestive problems.
This is a single case report, so we cannot determine how common this complication truly is. The patient’s pre-transplant celiac status is unknown, making it impossible to confirm whether celiac disease was truly new or was present but undiagnosed before treatment. The contribution of lenalidomide to the gastrointestinal symptoms could not be definitively excluded. The case lacks genetic testing (HLA-DQ2/DQ8) that would strengthen the celiac diagnosis. Finally, this is one patient’s experience, so findings cannot be generalized to all cancer patients receiving stem cell transplants.
The Bottom Line
Doctors should consider celiac disease in the differential diagnosis when cancer patients develop persistent gastrointestinal symptoms after stem cell transplant, particularly when infection and disease recurrence have been ruled out (moderate confidence based on case evidence). Testing should include upper endoscopy with duodenal biopsy and celiac serology (tissue transglutaminase IgA antibodies). A gluten-free diet is the proven treatment and can lead to rapid symptom resolution.
This finding is most relevant to hematologists and oncologists treating multiple myeloma and other cancers with stem cell transplants. Gastroenterologists should be aware when evaluating post-transplant patients with digestive complaints. Patients who develop diarrhea or weight loss after cancer treatment should discuss celiac disease testing with their doctors. People with a family history of celiac disease or autoimmune conditions may be at higher risk.
Based on this case, symptom improvement can occur rapidly, complete resolution of diarrhea occurred within 2 weeks of starting a gluten-free diet. Celiac antibody levels began declining over subsequent weeks and months. However, this timeline is based on a single patient and may vary.
Frequently Asked Questions
Can cancer treatment cause celiac disease to develop?
Stem cell transplants can trigger autoimmune diseases during immune system recovery, including celiac disease. One documented case showed a patient developing celiac disease 4 months post-transplant with complete symptom resolution on a gluten-free diet within 2 weeks.
What are the symptoms of celiac disease after cancer treatment?
Persistent diarrhea and unintentional weight loss are key symptoms. In the reported case, the patient lost 4 kg and had ongoing diarrhea 4 months after transplant. Intestinal biopsy and blood tests showing elevated celiac antibodies (>123 U/mL) confirmed the diagnosis.
How is celiac disease diagnosed in cancer patients?
Diagnosis requires upper endoscopy with intestinal biopsy showing villous atrophy, plus blood tests for tissue transglutaminase (tTG) IgA antibodies. In this case, antibody levels exceeded 123 U/mL, confirming celiac disease.
Does a gluten-free diet work for celiac disease after transplant?
Yes. The reported patient achieved complete diarrhea resolution within 2 weeks of starting a gluten-free diet, with declining celiac antibody levels confirming treatment effectiveness. This suggests the same dietary approach works regardless of when celiac disease develops.
Should cancer patients be screened for celiac disease before transplant?
This case suggests pre-transplant celiac screening may be valuable, as it could identify pre-existing disease and help distinguish new-onset celiac disease from medication side effects. However, current practice doesn’t routinely include this screening.
Want to Apply This Research?
- Track daily bowel movements and stool consistency (using the Bristol Stool Scale: 1-7 rating) along with any abdominal symptoms. Log gluten exposure and note timing of symptom changes. Record weekly weight to monitor for unintentional loss.
- Users receiving cancer treatment should log all gastrointestinal symptoms (diarrhea, bloating, weight changes) in their health app and share with their oncology team. If celiac disease is diagnosed, use the app to track gluten-free meals and identify hidden sources of gluten in medications and foods.
- Set weekly reminders to log symptom severity, weight, and dietary adherence. Create alerts if diarrhea persists beyond 1 week or weight loss exceeds 2 kg monthly. Track celiac antibody levels if available through lab results integration, monitoring for decline as confirmation of dietary compliance and disease improvement.
This case report describes a single patient’s experience and should not be considered medical advice. Celiac disease after stem cell transplant is extremely rare. If you are undergoing cancer treatment and develop persistent diarrhea, weight loss, or other gastrointestinal symptoms, consult your oncologist or gastroenterologist immediately. Do not self-diagnose or start a gluten-free diet without medical evaluation and testing. This information is for educational purposes and does not replace professional medical diagnosis or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
